Gene editing technology: Towards precision medicine in inherited retinal diseases
- 23 February 2021
- journal article
- other
- Published by Taylor & Francis in Seminars in Ophthalmology
- Vol. 36 (4) , 176-184
Abstract
Purpose: To review preclinical and clinical advances in gene therapy, with a focus on gene editing technologies, and application to inherited retinal disease. Methods: A narrative overview of the literature, summarizing the state-of-the-art in clinical gene therapy for inherited retinal disease, as well as the science and application of new gene editing technology. Results: The last three years has seen the first FDA approval of an in vivo gene replacement therapy for a hereditary blinding eye disease and, recently, the first clinical application of an in vivo gene editing technique. Limitations and challenges in this evolving field are highlighted, as well as new technologies developed to address the multitude of molecular mechanisms of disease. Conclusion: Genetic therapy for the treatment of inherited retinal disease is a rapidly expanding area of ophthalmology. New technologies have revolutionized the field of genome engineering and rekindled an interest in precision medicines for these conditions.Keywords
This publication has 129 references indexed in Scilit:
- Playing the End Game: DNA Double-Strand Break Repair Pathway ChoiceMolecular Cell, 2012
- Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 MutationsArchives of Ophthalmology (1950), 2012
- Exome sequencing and analysis of induced pluripotent stem cells identify the cilia-related gene male germ cell-associated kinase ( MAK ) as a cause of retinitis pigmentosaProceedings of the National Academy of Sciences, 2011
- CRISPR RNA maturation by trans-encoded small RNA and host factor RNase IIINature, 2011
- Novel Properties of Tyrosine-mutant AAV2 Vectors in the Mouse RetinaMolecular Therapy, 2011
- Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factorsProceedings of the National Academy of Sciences, 2010
- Vision 1 Year after Gene Therapy for Leber's Congenital AmaurosisNew England Journal of Medicine, 2009
- Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower dosesProceedings of the National Academy of Sciences, 2008
- Safety and Efficacy of Gene Transfer for Leber's Congenital AmaurosisNew England Journal of Medicine, 2008
- Effect of Gene Therapy on Visual Function in Leber's Congenital AmaurosisNew England Journal of Medicine, 2008